Jim Cramer runs the charitable trust portfolio, Action Alerts PLUS, and writes daily market commentary for TheStreet's RealMoney premium service. He also participates in video segments on TheStreet TV and serves as host of CNBC's "Mad Money" television program.
Cramer graduated magna cum laude from Harvard College, where he was president of The Harvard Crimson. He worked as a journalist at the Tallahassee Democrat and the Los Angeles Herald Examiner, covering everything from sports to homicide before moving to New York to help start American Lawyer magazine. After a three-year stint, Cramer entered Harvard Law School and received his J.D. in 1984. Instead of practicing law, however, he joined Goldman Sachs, where he worked in sales and trading. In 1987, he left Goldman to start his own hedge fund. While he worked at his fund, Cramer helped start Smart Money for Dow Jones and then, in 1996, he founded TheStreet. In 2000, Cramer retired from active money management to embrace media full time, including radio and television.
Cramer is the author of Confessions of a Street Addict," "You Got Screwed," "Jim Cramer's Real Money," "Jim Cramer's Mad Money," "Jim Cramer's Stay Mad for Life," "Jim Cramer's Getting Back to Even" and, most recently,"Get Rich Carefully." He has written for Time magazine and New York magazine and has been featured on CBS' 60 Minutes, NBC's Nightly News with Brian Williams, Meet the Press, Today, The Tonight Show, Late Night and MSNBC's Morning Joe
Trump may play the waiting game with China. This could weigh on the market.
Overwhelmed by the cannabis earnings reports? Here's the metric that Jim Cramer watches.
Let me tell you what I am hearing is the big sticking point in the talks with China.
I think sometimes the best way to parse the temperament is to go over the most obviously 'wrong' moves and address why they might not be wrong at all.
Jim Cramer said that he believes that Canopy Growth could be the next Amazon. Here's why he thinks that the cannabis company could be the next Amazon.
Jim Cramer wrote about the three different scenarios that could happen to Elon Musk as Judge Nathan considers her decision.
Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.
Jim Cramer says that Tilray's earnings call disappointed him. Here's why he wasn't blown away.
Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.
This is about an attack on the Judiciary, and Judge Alison Nathan is likely to act swiftly. How should Tesla shareholders respond?
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.